|
| Press Releases |
|
 |
|
| Friday, April 3, 2020 |
|
|
아방스 클리니컬, APAC 바이오테크 고객사들이 임상시험을 위해 호주를 선택하는 주요 이유 밝혀 |
| 호주의 임상시험수탁기관(CRO)인 아방스 클리니컬(Avance Clinical)은 클라이언트 온보딩 피드백을 토대로 APAC 바이오테크 기업들이 초기 임상시험을 위해 호주를 선택하는 주요 이유를 오늘 밝혔다. more info >> |
|
| Thursday, April 2, 2020 |
|
|
Avance Clinical on Top Reasons APAC Biotech Clients Choose Australia for Clinical Trials |
| Leading Australian CRO Avance Clinical today detailed the top reasons its APAC biotechs selected Australia for their early phase clinical trials, based on client onboarding feedback. more info >> |
|
| Friday, March 20, 2020 |
|
|
澳大利亞CRO, Avance Clinical公司在COVID-19疫苗和臨床試驗治療方案方面具有得天獨厚的優勢 |
| 澳大利亞CRO Avance Clinical今天表示，澳大利亞快速的監管審批環境，關鍵意見領袖的專業知識和高質量的臨床研究中心，以及頗具吸引力的40%的政府臨床試驗支出退稅，所有這一切都意味著Avance具有得天獨厚的優勢，能夠使緊迫的COVID-19試驗速見成效。 more info >> |
|
|
澳大利亚CRO, Avance Clinical公司在COVID-19疫苗和临床试验治疗方案方面具有得天独厚的优势 |
| 澳大利亚CRO Avance Clinical今天表示，澳大利亚快速的监管审批环境，关键意见领袖的专业知识和高质量的临床研究中心，以及颇具吸引力的40%的政府临床试验支出退税，所有这一切都意味着Avance具有得天独厚的优势，能够使紧迫的COVID-19试验速见成效。 more info >> |
|
|
호주 임상시험수탁기관인 아방스 클리니컬, COVID-19 백신 및 치료제 개발을 위한 임상시험에 독보적 위치 점유 |
| 호주의 임상시험수탁기관(CRO)인 아방스 클리니컬(Avance Clinical)은 호주의 빠른 규제 승인 환경과 주요 오피니언 리더들의 전문성, 고품질 임상 연구소 및 임상시험 지출에 대해 정부가 지급하는 40%의 보조금 등으로 인해 자신들이 COVID-19 관련 임상시험에서 신속히 결과를 낼 수 있는 유리한 위치에 있다고 오늘 밝혔다. more info >> |
|
|
Australian CRO, Avance Clinical is Uniquely Positioned for COVID-19 Vaccines and Therapies Clinical Trials |
| Australian CRO Avance Clinical said today that Australia's fast regulatory approval environment, key opinion leader expertise and high-quality clinical research sites, as well as the attractive 40% Government rebate on clinical trial spend, means Avance is uniquely positioned to deliver rapid results for urgent COVID-19 trials. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets
Feb 6, 2026 17:45 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 17:34: JST
|
|
|
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share
Feb 6, 2026 17:01 HKT/SGT
|
|
|
歌禮製藥-B（01672）獲新加坡政府投資公司首次入股 涉資約1億美元
Feb 6, 2026 16:56 HKT/SGT
|
|
|
歌礼制药-B（01672）获新加坡政府投资公司首次入股 涉资约1亿美元
Feb 6, 2026 16:50 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 16:34 HKT/SGT
|
|
|
トヨタ、役員人事を発表
Feb 6, 2026 16:00: JST
|
|
|
Distinct Healthcare Successfully Listed on HKEX, Bolstered by Premium Customer Base and All-Star Cornerstone Investors
Feb 6, 2026 15:55 HKT/SGT
|
|
|
Muyuan Foods Makes Hong Kong Debut Today: Strong Cornerstone Investor Backing Fuels Rapid Earnings Growth, Embarking on New Journey of Internationalization
Feb 6, 2026 15:40 HKT/SGT
|
|
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis
Feb 6, 2026 15:17: JST
|
|
|
牧原股份港股上市：全球生豬养殖龍頭 價值成長兼具
Feb 6, 2026 15:08 HKT/SGT
|
|
|
牧原股份港股上市：全球生猪养殖龙头 价值成长兼具
Feb 6, 2026 15:01 HKT/SGT
|
|
|
優異供應鏈賦能與國際化佈局雙輪驅動 綠茶開啟高質量成長新篇章
Feb 6, 2026 14:47 HKT/SGT
|
|
|
优异供应链赋能与国际化布局双轮驱动 绿茶开启高质量成长新篇章
Feb 6, 2026 14:33 HKT/SGT
|
|
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis
Feb 6, 2026 14:17 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
